Table 1.

Immunohistochemical results of EZHIP in our series

Tumor types	EZHIP [n (%)]
Diffuse astrocytic and oligodendroglial tumors
Astrocytoma, IDH-mutant, grade 2	0/2 (0)
Oligodendroglioma, IDH-mutant and 1p19q codeleted, grade 2	0/3 (0)
Epithelioid glioblastoma	0/1 (0)
Astrocytoma, IDH-mutant, grade 4	0/3 (0)
DMG, H3K27-mutant	0/24 (0)
DMG, H3K27-WT with EZHIP overexpression	13/13 (100)
HGG with MSI
CMMRD	0/6 (0)
Lynch syndrome	0/4 (0)
Diffuse glioma, H3.3 G34-mutant	0/10 (0)
HGG, MYCN-amplified	0/9 (0)
Glioblastoma, IDH-WT	0/10 (0)
Other astrocytic tumors
Pilocytic astrocytoma	0/10 (0)
High-grade astrocytoma with piloid features	0/1 (0)
Pleomorphic xanthoastrocytoma with anaplastic features	0/9 (0)
Ependymal tumors
Myxopapillary ependymoma	0/6 (0)
Posterior fossa ependymoma
Group PFA	47/47 (100)
Group PFA, H3K27-mutant	0/2 (0)
Group PFB	0/19 (0)
Supratentorial EPN
YAP1-fusion-positive	0/5 (0)
C11orf95 fusion-positive	0/17 (0)
Subependymoma	0/2 (0)
Neuronal and mixed neuronal-glial tumors
Diffuse leptomeningeal glioneuronal tumor	0/1 (0)
Tumors of the pineal region
Pineoblastoma	0/10 (0)
Embryonal tumors
Medulloblastoma, group 3	0/5 (0)
Medulloblastoma, group 4	0/5 (0)
Medulloblastoma, SHH-activated	0/10 (0)
Medulloblastoma, WNT-activated	1/10 (10)a
Embryonal tumors with multilayered rosettes, C19MC-amplified	0/10 (0)
AT/RT
AT/RT MYC	1/3 (33)a
AT/RT SHH	0/4 (0)
AT/RT TYR	0/3 (0)
CNS tumor with BCOR internal tandem duplication	0/8 (0)
CNS high-grade neuroepithelial tumor with MN1 alteration	0/8 (0)
Germ cell tumors
Germinoma	29/31 (94)

AT/RT atypical teratoid/rhabdoid tumor, CNS central nervous system, EPN ependymoma, HGG high-grade glioma, MSI microsatellite instability, WT wildtype

^a1 case presents a focal expression of EZHIP (< 1% of tumor cells)